BridgeBio Oncology Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $7.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $7.23M, a 725.94% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $3.87M, a 517.38% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $1.43M, a 85.55% increase year-over-year.
- BridgeBio Oncology Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $875.00K, a 213.62% increase year-over-year.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $7.23M 10-Q · filed 2026-08-11 | $11.10M derived: sum of 2 quarters · filed 2026-08-11 | |||
| 2026-03-31 | $3.87M 10-Q · filed 2026-08-11 | ||||
| 2025-12-31 | $5.87M POS AM · filed 2026-04-30 | ||||
| 2025-09-30 | $1.43M 10-Q · filed 2025-11-12 | $2.30M derived: sum of 2 quarters · filed 2026-08-11 | $2.93M derived: sum of 3 quarters · filed 2026-08-11 | ||
| 2025-06-30 | $875.00K 10-Q · filed 2026-08-11 | $36.00K 10-Q · filed 2025-08-01 | $1.50M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $627.00K 10-Q · filed 2026-08-11 | $57.92K 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | $2.29M POS AM · filed 2026-04-30 | ||||
| 2024-09-30 | $768.00K 10-Q · filed 2025-11-12 | $1.05M derived: sum of 2 quarters · filed 2025-11-12 | $1.71M derived: sum of 3 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $279.00K 10-Q · filed 2025-11-12 | $77.40K 10-Q · filed 2025-08-01 | $939.00K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $660.00K 10-Q · filed 2025-11-12 | $39.37K 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |